Elutia Inc

ELUT • Biotechnology

$0.82

— 0.00 (0.00%)

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$36.32M

Crecimiento

-30.2%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Múltiplo de ganancias razonable · 0.54Nivel de deuda manejable · 0.27Liquidez saludable · 2.22Tendencia de crecimiento negativa

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 16 ago 2026, 12:13 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$0.82

Change0.00%

Shares Out44.22M

Market Cap$36.32M

Enterprise Value$20.80M

52W Range0.50 - 2.50

Beta0.88

P/E0.70

P/S2.99

P/B2.31

P/FCF-0.80

EV/Sales1.71

Price$0.82

Change0.00%

Shares Out44.22M

Market Cap$36.32M

Enterprise Value$20.80M

52W Range0.50 - 2.50

Beta0.88

P/E0.70

P/S2.99

P/B2.31

P/FCF-0.80

EV/Sales1.71

EV/EBITDA-1.16

EV/FCF-0.46

Earnings Yield142.66%

FCF Yield-125.22%

Dividend Yield0.00%

Gross Margin53.66%

Oper. Margin-149.78%

Profit Margin4.34%

Debt/Eq0.27

Current Ratio2.22

Quick Ratio2.12

Revenue 5Y-30.15%

Target$8.88

Target Upside981.34%

Target Median$10.00

Target Range5.00 - 10.50

Volume66.98K

Avg Volume96.11K

EPS Surprise-0.02

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

43/100

Fortaleza financiera

Deuda, caja, estabilidad

95/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

92/100

Por qué este puntaje▼

Múltiplo de ganancias razonable · 0.54Nivel de deuda manejable · 0.27Liquidez saludable · 2.22Tendencia de crecimiento negativa

Analyst view

Analyst sentiment and price target

ELUT

Analyst sentiment

Based on 5 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-16

Bajo

$5.00

Promedio

$8.88

Mediana

$10.00

Alto

$10.50

Resumen de la compañía

IPO: 10/7/2020

Industria: Biotechnology

P/B i: 2.31

Deuda / Patrimonio i: 0.27

Margen operativo: -149.78%

Margen neto: 4.34%

ROE i: -

ROIC: -

Salud financiera

Puntaje19 / 20

Deuda / Patrimonio: 0.27

Ratio corriente: 2.22

Ratio rápido: 2.12

Estado: Strong

Transacciones internas

Actividad reciente de ejecutivos e insiders

Mills C Randal

Transacción: 06/21/2026

VENTA

Cambio

-22,473

Precio

Not reported

Presentación

06/22/2026

Tipo

VENTA

Mills C Randal

Transacción: 06/21/2026

VENTA

Cambio

-8,064

Precio

$1.06

Presentación

06/22/2026

Tipo

VENTA

Makes Brigid

Transacción: 06/11/2026

COMPRA

Cambio

+106,393

Precio

$0.96

Presentación

06/15/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Mills C Randal	VENTA	-22,473	Not reported	06/21/2026	06/22/2026
Mills C Randal	VENTA	-8,064	$1.06	06/21/2026	06/22/2026
Makes Brigid	COMPRA	+106,393	$0.96	06/11/2026	06/15/2026
NEELS GUIDO J	COMPRA	+106,393	$0.96	06/11/2026	06/15/2026
Colpman David	COMPRA	+106,393	$0.96	06/11/2026	06/15/2026
RAKIN KEVIN	COMPRA	+159,590	$0.96	06/11/2026	06/15/2026
Mills C Randal	VENTA	-27,083	Not reported	06/10/2026	06/12/2026
Mills C Randal	VENTA	-9,718	$1.04	06/10/2026	06/12/2026
Ferguson Matthew	VENTA	-12,500	Not reported	06/10/2026	06/12/2026
Ferguson Matthew	VENTA	-4,485	$1.04	06/10/2026	06/12/2026
Williams Michelle LeRoux	VENTA	-12,500	Not reported	06/10/2026	06/12/2026
Williams Michelle LeRoux	VENTA	-4,269	$1.04	06/10/2026	06/12/2026
RAKIN KEVIN	VENTA	-70,000	Not reported	06/01/2026	06/02/2026
NEELS GUIDO J	VENTA	-6,250	Not reported	12/10/2025	04/14/2026
NEELS GUIDO J	COMPRA	+6,250	Not reported	12/10/2025	04/14/2026
Ferguson Matthew	VENTA	-12,500	Not reported	03/10/2026	03/12/2026
Mills C Randal	VENTA	-27,084	Not reported	03/10/2026	03/12/2026
Mills C Randal	VENTA	-11,100	$1.09	03/10/2026	03/12/2026
Ferguson Matthew	VENTA	-5,123	$1.09	03/10/2026	03/12/2026
Williams Michelle LeRoux	VENTA	-12,500	Not reported	03/10/2026	03/12/2026

Sobre la compañía

Elutia Inc

Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.

Fuente - Link

Competidores

ANVS BCAB CALC CELU LTRN MAIA PYPD RNXT RVPH TVRD

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference

GAITHERSBURG, Md., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, Chief Executive Officer, Matthew Ferguson, Chief Financial Officer, and Dr. Michelle Williams, Chief Scientific Officer, will participate in two upcoming investor conferences.

GlobeNewsWire

Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.

ROSWELL, Ga., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Cellution Biologics Inc. (“Cellution Biologics” or the “Company”), a biologics company focused on developing, manufacturing and commercializing advanced human tissue-based products, today announced the completion of its acquisition of the SimpliDerm hydrated human acellular dermal matrix (ADM) business from Elutia Inc. (Nasdaq: ELUT).

GlobeNewsWire

Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch

Deal valued at $11 million in cash, with $8 million at closing and up to $3 million in additional milestone payments over the next 18 months Divestiture further concentrates Elutia's attention and resources on the development and commercialization of NXT-41x NXT-41x is an antibiotic-eluting biomatrix designed to address post-operative infection in the $1.5 billion U.S. plastic and reconstructive surgery market NXT-41x clearance expected in the first half of 2027 GAITHERSBURG, Md., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced it completed the sale of its SimpliDerm® human acellular dermal matrix business to Cellution Biologics Inc. for total consideration of up to $11 million.

GlobeNewsWire

Elutia Inc. (ELUT) Q2 2026 Earnings Call Transcript

Seeking Alpha

Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results

Funded through launch: secured up to $26 million of capital without an equity offering The unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection risk The demand is strong: 96% of surgeons surveyed are interested in adopting NXT-41x; 92% responded they would champion it at their hospital value analysis committee On track: NXT-41 FDA clearance decision expected in 4Q 2026; NXT-41x FDA clearance decision expected in 1H 2027 GAITHERSBURG, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and announced financial results for the second quarter ended June 30, 2026.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-14	-0.15	-0.17	-0.02
2026-03-11	-0.14	-0.14	0
2025-11-06	-0.155	-0.01	0.145
2025-08-14	-0.17	-0.26	-0.09
2025-05-08	-0.2	-0.21	-0.01
2025-03-06	-0.25	-0.26	-0.01
2024-11-14	-0.44	-0.33	0.11
2024-08-07	-0.33	-1.14	-0.81
2024-05-09	-0.41	-0.75	-0.34
2024-03-07	-0.28	-0.66	-0.38
2023-11-13	-0.53	-0.5	0.03
2023-08-14	-0.29	-0.65	-0.36